Navigation Links
China Pharma Holdings, Inc. Projects 3rd Quarter 2008 Revenue Growth to Exceed 40%
Date:9/18/2008

Revenue Guidance with Q3 2008 Forecasts Growth of More Than 40%

NEW YORK and HAIKOU CITY, Hainan, China, Sept. 18 /Xinhua-PRNewswire- FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI) which develops, manufactures, and markets generic and brand bio-pharmaceutical products in China, announced today that it projects the 3rd Quarter 2008 revenue growth to exceed 40%.

According to recent sales figures, China Pharma is adjusting its projected Q3 revenue growth upwards to between 40% and 45%.

Ms. Zhilin Li, President and CEO of China Pharma, commented, "We are very pleased that the sales this quarter have exceeded our prediction. This reflects the expansion of our sales force and our continued efforts to increase penetration of our distribution network."

Ms Li continued, "The global capital markets are experiencing a downturn, and the Chinese economy is also tending towards a decline. Our share price has suffered, however we are able to take advantage of the company's very stable platform for growth and continue our good performance. We believe revenue and earnings will maintain continued long-term growth and that this is the best reward for investors. We consider this a good opportunity to communicate and share our confidence on the company outlook with our fellow shareholders."

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. develops, manufactures, and markets off-patent brand bio-pharmaceutical products in China that treat a wide range of conditions, including, cardiovascular and CNS diseases, infections, liver disease and other prevalent diseases. Helpson Bio-pharmaceutical Co., Ltd. (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. For more information about China Pharma Holdings, Inc., please visit http:/
'/>"/>

SOURCE China Pharma Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... , NEW YORK, Nov. 25 Reportl...ort is available in its catalogue: ,, Brazil B..., http://www.reportlinker.com/p0165503/Brazil-...tml ,, Brazil Bioethanol Market Analysis and F...provides detailed analysis and forecasts of the gl...
(Date:11/24/2009)... The New York investment bank KTA ...EU) has agreed an AU$6.7 mil convertible note priv...The private placement was arranged by KTA Capital ... , New York (PRWEB) Novem...t bank KTA Capital, LLC ("KTA Capital") ...
(Date:11/24/2009)... Health care employment grew by ...only one to show consistent growth during the U.S....ls remain in trouble, and health systems are comin...el, instead of just administrators. , ...are employment continued growing in October despit...
(Date:11/24/2009)...EATTLE,Nov.24/PRNewswire/--BlueMarbleEnergyCorp.an...pmentAuthority(OPDA)wererecentlyawarded$2millionby...ard(CERB)inaprivate/publicpartnershiptoconstructth...olnCounty,WA. ,, "Thisinvestmentwillsignificant...0greenjobstoLincolnCounty,"saidBlueMarbleEnergyCEO...
Breaking Biology Technology:Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 10KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2
...lcers each year in the US, PRINCETON, N.J., March...), provider of advanced wound care products,announ... the clinical usage,of its newly released MEDIHONE...mum Honey presented at the annual American Profess...ld the second week in March in Forth,Worth, Texas,...
...aunch..., WAYLAND, Mass., March 20 Tourtellotte ...linical trials software, announces the,launch of i...rm for phase,II-IV studies. Trident,s unique param...of legacy IVRS technologies and promises to delive...nd ease-of-use to the straining,global clinical IV...
...nc., a,pioneer in drug discovery from marine micro...begun in a Phase 1b study evaluating the vascular,...h standard chemotherapy,in patients with non-small...ositive outcomes in a Phase 1 single-agent clinica...armacodynamics (PK/PD) and efficacy of NPI-2358,in...
Other Biology Technology:Derma Sciences Announces Clinical Poster on Use of MEDIHONEY(TM) Wound & Burn Dressings Wins First Place Award at APWCA 2Derma Sciences Announces Clinical Poster on Use of MEDIHONEY(TM) Wound & Burn Dressings Wins First Place Award at APWCA 3Derma Sciences Announces Clinical Poster on Use of MEDIHONEY(TM) Wound & Burn Dressings Wins First Place Award at APWCA 4Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 2Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 3Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data 2Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data 3
(Date:11/24/2009)...t keep weakened and flabby arteries from collapsin..., those stents are no longer needed -- once the ar...Previously, doctors had no choice but to leave the... University,s Department of Biomedical Engineering... that carries drugs where they,re needed, then dis...
(Date:11/24/2009)...UGE Antarctica has long held secrets of the earth...ently, there has been very little information on t...s of ice for millions of years. Now, a team of res...ve been funded to the tune of $10 million dollars ... to the bottom of things literally. These scienti...
(Date:11/23/2009)...New research presents strong evidence that the "sy...utdoor traffic-related pollution and indoor endoto...or the other exposure alone. , Environmental h...UC) College of Medicine have shown that children e...icles and indoor endotoxin during early life are s...
Breaking Biology News(10 mins):A coating for life 2LSU gets to the bottom of things -- in Antarctica 2Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 1ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 2ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 3ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 4ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 5ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 6ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 7Jackson 26amp 3B Coker Industry Report Addresses Health Care Reform 62010 1Jackson 26amp 3B Coker Industry Report Addresses Health Care Reform 62010 2Jackson 26amp 3B Coker Industry Report Addresses Health Care Reform 62010 3Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 62008 1Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 62008 2Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 62008 3
...AMBRIDGE, Mass. (April 2, 2009) Whitehead Institu...ifiable prion proteins in yeast and have further c...f both beneficial and detrimental traits. , "The ...al are they evolved to be prions, or are they alw...," says Randal Halfmann, a research assistant in W...
...New diseases directly affect human survival and fo...bs. Leaf-cutting ants, one of a few groups of soci...t material to fertilize their underground fungal g... Smithsonian show that both the ants and their fun...t inside leaves, thus ensuring the health of their...
...AMBRIDGE, Mass.--Each year, hundreds of thousands ...rmic needles that penetrate too far under their sk...lleagues aims to prevent this from happening by ke...urely mechanical, is based on concepts borrowed fr... needle containing a filament that acts as a guide...
Other Biology News:Redefining what it means to be a prion 2Redefining what it means to be a prion 3Food security for leaf-cutting ants: Workers and their fungus garden reject endophyte invaders 2MIT: Novel needle could cut medical complications 2
UltraClean GelSpin Kit from Mo Bio Laboratories, Inc.
Rabbit Complement Lyophilized Powder from Equitech-Bio
Rabbit Anti-Human Histone H3, phospho (Ser10 / Ser28) Polyclonal Antibody, Unconjugated from Lake Placid Biologicals
UltraClean GelSpin Kit from Mo Bio Laboratories, Inc.
Biology Products: